mRNA Clinical Trial Enabling Infrastructure Grant

What is the mRNA Clinical Trial Enabling Infrastructure Grant?

The mRNA Clinical Trial Enabling Infrastructure Grant opportunity is a program that provides organisations with funding to use and enhance emerging technologies, platforms, equipment and infrastructure to conduct clinical trials of mRNA-based vaccines and/or therapeutics.

Background

The 2021 mRNA Clinical Trial Enabling Infrastructure grant is part of the Medical Research Future Fund (MRFF) and the Coronavirus Research response. This opportunity looks to fund an organisation who has applied to the Department of Industry, Science, Energy and Resources (DISER) and Department of Health’s Approach To Market: Enabling Australia’s onshore mRNA manufacturing capability. In addition, they must specify at least one state government partner organisation contributing to the research.

The objective of this grant opportunity is to provide funding to Australian medical research and medical innovation projects that leverage and enhance emerging technologies, platforms, equipment and infrastructure to conduct clinical trials of mRNA-based vaccines and/or therapeutics.

Funding

A fixed grant amount of $5 million over 3 years from 2022-23 to develop our onshore mRNA vaccine manufacturing capability.

Eligible Projects

The program can only accept applications where you can provide:

details of your nominated Chief Investigator A (CIA) who will take the lead role in conducting the project
evidence from your board (or chief executive officer or equivalent if there is no board) that the project is supported, and that you can complete the project and meet the costs of the project not covered by grant funding
letters of support from each project partner
all mandatory attachments.

To be eligible your project must:

be aimed at the objectives
include one or more of the following eligible activities:
- minor capital works
- development/installation of research equipment
- employment of personnel and/or
- other direct research costs.

Eligible Applicants

You can apply if you:

have an Australian business number (ABN)
are incorporated in Australia

You must also be one of the following entities:

a medical research institute
a university
a corporate Commonwealth entity
a corporation (including businesses and not for profits).

In addition you or a partner organisation must have applied to the (DISER) and Department of Health’s Approach To Market: Enabling Australia’s onshore mRNA manufacturing capability program and must have at least one state government partner organisation.

You can’t apply if you are:

an organisation, or your project partner is an organisation, included on the National Redress Scheme’s list of Institutions that have not joined or signified their intent to join the Scheme– external site
an employer of 100 or more employees that has not compliedwith the Workplace Gender Equality Act (2012)
an individual
partnership
unincorporated association
trust (however, an incorporated trustee may apply on behalf of a trust)
a non-corporate Commonwealth entity.

Timing

Applications close 15 July 2022.

More Information

What is the #1 grant for start-ups?

12,000+ companies access the R&D tax incentive per year that yields a CASH REBATE of up to 43.5%.
This might be perfect your start up.
Do you want to know more?

Bulletpoint is a Melbourne-based consultancy specialising in guiding businesses through the complex process of the R&D tax incentive. With a decade of experience under our belt, we’re proud to be led by Australia’s highest-rated R&D tax consultant. We’ve successfully lodged over 500 R&D claims, demonstrating a proven track record.

Our approach is straightforward and personable, focusing on cutting through the jargon to help businesses truly understand the definition of R&D in government terms. We’re passionate about what we do, and our clients appreciate this, often commenting on the difference our expertise has made to their businesses. They’ve praised us for uncovering grants they wouldn’t have otherwise known about and for making the whole process less stressful for them.

We’re proud to have an average rating of 4.8 stars from over 250 Google reviews. Despite our success, we continue to strive for improvement, learning from every piece of feedback we receive.

At Bulletpoint, we excel in helping businesses navigate the complexities of the R&D tax incentive process, ensuring they reap the benefits they deserve. As experts in our field, we’re well-versed in what works and what doesn’t when it comes to aligning businesses’ perceptions of R&D with the government’s eligibility criteria.

So, if you’re looking for accessible expertise and a proven success rate, you’ll find it with us at Bulletpoint. We’re ready to guide you through the R&D tax incentive process with a blend of professionalism and personality, ensuring your experience with us is not just successful, but enjoyable as well.